Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo

Background Interleukin 12 (IL‐12), one of the most potent Th1‐cytokines, has been used to improve dendritic cells (DC)‐based immunotherapy of cancer. However, it failed to achieve clinical response in patients with hepatocellular carcinoma (HCC). In this study, improved conditions of immunotherapy w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Liver international 2014-03, Vol.34 (3), p.447-461
Hauptverfasser:	Vogt, Annabelle, Sievers, Elisabeth, Lukacs-Kornek, Veronika, Decker, Georges, Raskopf, Esther, Meumann, Nadja, Büning, Hildegard, Sauerbruch, Tilman, Strassburg, Christian P., Schmidt-Wolf, Ingo G. H., Gonzalez-Carmona, Maria A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae - genetics Animals Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - therapy CD4-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - immunology Cell Line, Tumor Cytokines - metabolism Cytotoxicity, Immunologic dendritic cells Dendritic Cells - immunology hepatocellular carcinoma Humans IL-12 immunosuppressive tumour-environment Immunotherapy Interleukin-12 - genetics Liver Neoplasms - therapy Mice Mice, Inbred C3H Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!